FORM 6 - K
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16 of
The Securities Exchange Act of 1934
For the month of September 2000
Commission File Number 0-29350
VASOGEN INC.
(Translation of Registrant's name into English)
2155 Dunwin Drive, Suite 10, Mississauga, Ontario, L5L 4M1
(Address of principal executive offices)
(Indicate by check mark whether the registrant files or will file annual reports
under cover Form 20 - F or Form 40 - F.)
Form 20 - F [X] Form 40 - F [_]
(Indicate by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of
1934.)
Yes [_] No [X]
This Form 6-K consists of:
A press release issued by Vasogen Inc. on September 25, 2000, entitled: "Vasogen
to Conduct Third Quarter Conference Call".
SIGNATURE
---------
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
VASOGEN INC.
By /s/ Christopher Waddick
---------------------------------------
(Name: Christopher Waddick)
(Title: Vice-President, Finance & CFO)
Date: September 25, 2000
<PAGE>
Vasogen Inc.
INVESTOR CONTACT
2155 Dunwin Drive
Mississauga, ON, Canada L5L 4M1 Glenn Neumann
tel: (905) 569-2265 fax: (905) 569-9231 Investor Relations
www.vasogen.com tel: (905) 569-9065
e-mail: [email protected]
--------------------------------------------------------------------------------
FOR IMMEDIATE RELEASE
Vasogen to Conduct Third Quarter Conference Call
Toronto, Ontario (September 25, 2000) -- Vasogen Inc. (TSE:VAS; AMEX:MEW) will
conduct its third quarter conference call on Wednesday, September 27, 2000 at
4:10 p.m. Eastern Time to provide a regular quarterly update on corporate
developments. The conference will also be available via audio webcast.
Participants are invited to attend by connecting 10 minutes prior to the call to
one of the following:
Direct Dial 416-231-6596
------------------------------- -----------------------------
Toll-free 800-361-1028
------------------------------- -----------------------------
Audio Webcast* www.vasogen.com
------------------------------- -----------------------------
*RealPlayer required
The conference call will be re-broadcast until October 4, 2000 and may be
accessed by calling:
--------------------- ------------------------- --------------------------
Direct Dial 416-640-1917 Passcode: 64987#
--------------------- ------------------------- --------------------------
The audio webcast will also be available for replay via Vasogen's website at
www.vasogen.com.
Vasogen is focused on developing immune modulation therapies to advance the
treatment of cardiovascular, autoimmune and related inflammatory diseases.
These therapies are designed to target fundamental disease-causing events,
providing safe, effective treatment.
Statements contained in this press release, and in the upcoming conference call,
including those pertaining to scientific and clinical research,
commercialization plans, strategic alliances, and intellectual property
protection, other than statements of historical fact, are forward-looking
statements subject to a number of uncertainties that could cause actual results
to differ materially from statements made.
